ARTICLE | Clinical News
IBPI completes Phase III iseganan enrollment
December 6, 2001 8:00 AM UTC
IntraBiotics (IBPI) completed enrollment in the second of 3 placebo-controlled Phase III trials of its iseganan oral solution to reduce the severity of oral mucositis in 544 head and neck cancer patie...